SHSE:688513 (China)
Â
Class A
Â¥
40.38
(+10%)
Sep 30
Business Description
Chengdu Easton Biopharmaceuticals Co Ltd
ISIN : CNE100004397
Share Class Description:
SHSE:688513: Class ACompare
Compare
Traded in other countries / regions
688513.China IPO Date
2020-09-02Description
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.1 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.97 | |||||
| Interest Coverage | 56.93 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 6.04 | |||||
| Beneish M-Score | -1.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.4 | |||||
| 3-Year EBITDA Growth Rate | 4.5 | |||||
| 3-Year EPS without NRI Growth Rate | 5 | |||||
| 3-Year Book Growth Rate | 7.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 36.84 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 23.26 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 91.55 | |||||
| 9-Day RSI | 82.29 | |||||
| 14-Day RSI | 75.57 | |||||
| 6-1 Month Momentum % | -7.61 | |||||
| 12-1 Month Momentum % | -4.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.66 | |||||
| Quick Ratio | 2.42 | |||||
| Cash Ratio | 2 | |||||
| Days Inventory | 225.81 | |||||
| Days Sales Outstanding | 44.88 | |||||
| Days Payable | 233.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.44 | |||||
| Dividend Payout Ratio | 0.43 | |||||
| Forward Dividend Yield % | 1.44 | |||||
| 5-Year Yield-on-Cost % | 1.44 | |||||
| Shareholder Yield % | 0.22 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.85 | |||||
| Operating Margin % | 18.62 | |||||
| Net Margin % | 19.62 | |||||
| FCF Margin % | 6.87 | |||||
| ROE % | 9.31 | |||||
| ROA % | 7.3 | |||||
| ROIC % | 13.12 | |||||
| 3-Year ROIIC % | 2.44 | |||||
| ROC (Joel Greenblatt) % | 21.11 | |||||
| ROCE % | 9.76 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 29.43 | |||||
| Forward PE Ratio | 21 | |||||
| PE Ratio without NRI | 29.8 | |||||
| Price-to-Owner-Earnings | 146.84 | |||||
| PEG Ratio | 3.04 | |||||
| PS Ratio | 5.78 | |||||
| PB Ratio | 2.67 | |||||
| Price-to-Tangible-Book | 2.77 | |||||
| Price-to-Free-Cash-Flow | 83.25 | |||||
| Price-to-Operating-Cash-Flow | 29.87 | |||||
| EV-to-EBIT | 19.96 | |||||
| EV-to-EBITDA | 19.96 | |||||
| EV-to-Revenue | 4.22 | |||||
| EV-to-FCF | 61.43 | |||||
| Price-to-Graham-Number | 1.92 | |||||
| Price-to-Net-Current-Asset-Value | 5.97 | |||||
| Price-to-Net-Cash | 10.38 | |||||
| Earnings Yield (Greenblatt) % | 5.01 | |||||
| FCF Yield % | 1.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chengdu Easton Biopharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,231.277 | ||
| EPS (TTM) (Â¥) | 1.372 | ||
| Beta | 0.17 | ||
| Volatility % | 40.83 | ||
| 14-Day RSI | 75.57 | ||
| 14-Day ATR (Â¥) | 1.641706 | ||
| 20-Day SMA (Â¥) | 34.9905 | ||
| 12-1 Month Momentum % | -4.21 | ||
| 52-Week Range (Â¥) | 28.11 - 43.707482 | ||
| Shares Outstanding (Mil) | 176.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chengdu Easton Biopharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chengdu Easton Biopharmaceuticals Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Chengdu Easton Biopharmaceuticals Co Ltd Frequently Asked Questions
What is Chengdu Easton Biopharmaceuticals Co Ltd(SHSE:688513)'s stock price today?
The current price of SHSE:688513 is ¥40.38. The 52 week high of SHSE:688513 is ¥43.71 and 52 week low is ¥28.11.
When is next earnings date of Chengdu Easton Biopharmaceuticals Co Ltd(SHSE:688513)?
The next earnings date of Chengdu Easton Biopharmaceuticals Co Ltd(SHSE:688513) is .
Does Chengdu Easton Biopharmaceuticals Co Ltd(SHSE:688513) pay dividends? If so, how much?
The Dividend Yield %  of Chengdu Easton Biopharmaceuticals Co Ltd(SHSE:688513) is 1.44% (As of Today), Highest Dividend Payout Ratio of Chengdu Easton Biopharmaceuticals Co Ltd(SHSE:688513) was 0.57. The lowest was 0.26. And the median was 0.43. The  Forward Dividend Yield % of Chengdu Easton Biopharmaceuticals Co Ltd(SHSE:688513) is 1.44%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers